No Detail Found!

Clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy

Author(s)
Jie Liu Department of Endocrinology, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Jing Zhang Department of Cardiology, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Ming-hui Hou Department of Endocrinology, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Wei-xuan Du Department of Education, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Abstract
Objective: To determine the clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy (DN). Methods: Seventy-two patients who were admitted to our department of endocrinology in our hospital during January 2018 and June 2019 were randomly divided into a control group (administered with irbesartan only, n=36) and a treatment group (treated with irbesartan and linagliptin, n=36). The course of treatment lasted for three months. FBG (fasting blood glucose), 2hPBG (2h postprandial blood sugar), HbA1C (hemoglobin A1c), Cys-C (cystatin C), SCr (serum creatinine), BUN (blood urea nitrogen), UACR (urine albumin-to-creatinine ratio), CRP (C-reactive protein), IL-6 (interleukin-6), and SOD (superoxide dismutase) were tested pre- and post-treatment to evaluate the clinical efficacy and adverse effects of the two treatment plans after three months of treatment. Results: Compared with the pre-treatment levels, FBG, 2hPBG, HbA1c, Cys-C, SCr, BUN, UACR, CRP, IL6, and SOD in both groups were significantly improved following the three-month treatment (P0.05). Conclusion: Combined-modality treatment with linagliptin and irbesartan shows favorable clinical efficacy in treating diabetic nephropathy as it effectively protects the kidneys and improves kidney function by inhibiting inflammatory and oxidative stress responses.
Publication Details
Page(s) 52-56
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 38, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Irbesartan, Diabetic Nephropathy, Linagliptin
0

Citations

0

Downloads

79

Views